Disease

Cardiometabolic Disease

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 1 TRIAL

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

ClinicalTrials.gov

This is a Phase 1 safety and tolerability study with no results posted; the registry record describes planned enrollment and endpoints only, without outcome data.

PreliminaryCardiometabolic Disease Amgen AMG 513

Reported

Planned enrollment82

Study phasePhase 1

Primary outcome measureNumber of Participants With Treatment-emerg…

AUG 26, 2026 · JOURNAL ARTICLE

Sex differences in the gut microbiome and related metabolites: role in cardiometabolic disease.

Gut Microbes

A narrative review synthesizing evidence on sex differences in gut microbiome and cardiometabolic disease, providing an integrative summary rather than new empirical data or a definitive trial.

Expert GuidanceEn Cheng Brandilyn A Peters-Samuelson Metabolic Diseases

Reported

Gut microbiome microbial density10^13 to 10^14 microorganisms

Gene encoding capacity150-fold more genes than human genome

AUG 6, 2026 · JOURNAL ARTICLE

Lifestyle modifications in individuals with blood pressure beyond treatment target despite pharmacological treatment: design and baseline characteristics of the MeDiPA randomised controlled trial.

Blood Pressure

This is a design paper reporting baseline characteristics of a small RCT (n=66) not yet reporting efficacy outcomes; the trial will generate evidence but no treatment effect data are presented.

PreliminaryMette Svendsen Hypertension Reza Ghiasvand

Reported

Age, mean (SD)59 (8) years

Female participants56%

Baseline office BP, mean (SD)137 (15)/90 (8) mmHg